Guangzhou, China– August , 2024 – Inc. “The EC approval of BAT2206 is anothersignificant accomplishment for Bio-Thera as it marks Bio-Thera’s third EC approvedproduct” said Shengfeng Li, CEO at Bio-Thera. “Bio-Thera is committed toexpanding access fo...
View Detailshas reached a licensing agreement with for BAT06, its biosimilar, under which will have exclusive rights to distribute and market the drug in BATis a proposed biosimilar for the treatment of Bio-Thera’s BAT1706 has successfully completed a global Pha...
GUANGZHOU, China--(BUSINESS WIRE)--Bio-Thera Solutions (SHA: 688177), a commercial-stage biopharmaceuticalcompany, today announced that it has submitted the MAA for BAT1706, a proposed biosimilar to Avastin® (bevacizumab), to EMA. Bio-Thera seeks a c...
GUANGZHOU, and BEIJING, China and CAMBRIDGE, Mass, Aug 24, 2020 – Bio-Thera Solutions,Ltd.,a commercial stage biopharmaceutical company (688177.SH) and BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), today announced that the companies have executeda licen...
